Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs United Airlines Holdings Inc (UAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs United Airlines Holdings Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.60B), while United Airlines Holdings Inc trades at $126.31 (market cap $41.00B). The key difference: United Airlines Holdings Inc is the larger of the two by market cap, and United Airlines Holdings Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | UAL | |
|---|---|---|
Market Cap | $29.60B | $41.00B |
Sector | Health | Industrials |
52-Week High | $491.22 | $136.11 |
52-Week Low | $205.48 | $85.21 |
Enterprise Value | $27.56B | $58.03B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.
The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.
United Airlines (UAL) trades at $125.37, up 1.3% today, with a bullish technical signal from moving averages. The stock shows strong fundamentals with a low P/E of 11.83 and robust ROE of 23.25%. Recent earnings have consistently beaten estimates, and revenue is projected to grow to $62.9B in 2026. Analyst sentiment is overwhelmingly positive with a $167.73 consensus price target and no sell ratings.
The outlook for UAL is favorable due to solid earnings momentum and improving debt metrics, though risks include fuel cost volatility and execution of fleet innovation. The stock presents a value opportunity with upside potential, supported by strong institutional buy-in and manageable liabilities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About United Airlines Holdings Inc
United Airlines is a major U.S. network carrier. United's hubs include San Francisco, Chicago, Houston, Denver, Los Angeles, New York/Newark, and Washington, D.C. United operates a hub-and-spoke system that is more focused on international travel than legacy peers.
Read more on UAL →
